Written question asked by Philip Dunne (Conservative) on Monday, 9 October 2006, in the House of Commons. It was due for an answer on Wednesday, 11 October 2006. It was answered by Baroness Winterton of Doncaster (Labour) on Thursday, 19 October 2006 on behalf of the Department of Health.

Rosiglitazone

Question: To ask the Secretary of State for Health (1) when Rosiglitazone is expected to be made available to patients most at risk of developing diabetes;

Answer

Rosiglitazone is not licensed for the prevention of type 2 diabetes.No estimate has been made of the likely annual cost to the national health service of providing Rosiglitazone to those likely to benefit from it. However, the following data shows the current costs to the NHS for prescribing Rosiglitazone:

Net ingredient costs for the dispensing of glitazones
Dispensing in the community
£
	Pioglitazone	Metformin/Rosiglitazone	Rosiglitazone
2005-06	15,794,860	13,420,190	46,822,312

Dispensing in hospitals
£
	Pioglitazone	Metformin/Rosiglitazone	Rosiglitazone
2005-06	255,752	34,939	607,218

The National Institute for Health and Clinical Excellence (NICE) published recommendations in 2003 on the use of glitazones for the treatment of type 2 diabetes. NICE is currently reviewing this guidance as part of a review of all of its type 2 diabetes guidance which is due to be published in February 2008.I have received no representations about the estimated number of patients who would benefit from Rosiglitazone.

Secondary information

Type: Written question
Reference: 93260; 450 c1431-2W;450 c1437-8W
Session: 2005-06
Subjects: Diabetes Drugs
Link: View this Written question on www.publications.parliament.uk

Rosiglitazone

Secondary information

Librarians' tools